A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Academic Article uri icon

Overview

publication date

  • April 17, 2025

Identity

PubMed Central ID

  • PMC12054645

Scopus Document Identifier

  • 105004648510

Digital Object Identifier (DOI)

  • 10.3389/fmed.2025.1548590

PubMed ID

  • 40330782

Additional Document Info

volume

  • 12